Report Shows Record Number of Cancer Drugs in Development

Publication
Article
OncologyONCOLOGY Vol 23 No 4
Volume 23
Issue 4

Responding to President Obama’s call for “a cure for cancer in our time,” the Pharmaceutical Research and Manufacturers of America recently delivered a new report on drugs in the research pipeline for cancer.

Responding to President Obama's call for "a cure for cancer in our time," the Pharmaceutical Research and Manufacturers of America recently delivered a new report on drugs in the research pipeline for cancer. The report shows that America's pharmaceutical research and biotechnology companies are testing a record 861 new cancer medicines and vaccines. The drugs listed in the report are being tested in human clinical trials or are awaiting approval by the US Food and Drug Administration.

Articles in this issue
Despite Past Disappointments the Future of Melanoma Therapy Appears Bright
Everolimus Approved for Advanced Kidney Cancer
Report Shows Record Number of Cancer Drugs in Development
Sunitinib Study in Pancreatic Cancer Stopped Early After Significant Benefit Seen
Black Cohosh (Cimicifuga racemosa)
Black Cohosh (Cimicifuga racemosa)
Clinical Trials and Radiation Oncology Technologies
Evaluating Advanced Technologies in Radiation Oncology: When and How Should Randomized Trials Be Done?
Current Status and Future Potential of Advanced Technologies in Radiation OncologyPart 2. State of the Science by Anatomic Site
Health Literacy: Improving Patient Understanding
Health Literacy, Communication, and Treatment Decision-Making in Older Cancer Patients
The Role of Adjuvant Radiation in Endometrial Cancer
The Role of Adjuvant Radiation in Endometrial Cancer
Resolving the Confusion Surrounding Adjuvant Radiation in Endometrial Cancer
Studies of Adjuvant Treatment for Endometrial Cancer
Landmark Study Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer
Maintenance Rituximab Useful in Advanced Indolent Lymphoma
Recent Videos
Related Content
Teclistamab Real-World Data and Trial Results Show Promise in R/R Multiple Myeloma

Teclistamab Real-World Data and Trial Results Show Promise in R/R Multiple Myeloma

ONCOLOGY Staff
August 19th 2025
Article

Experts discussed teclistamab's efficacy in multiple myeloma, highlighting real-world data and treatment protocols.

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

Analyzing Long-Term Follow-Up Results From MonumenTAL-1 in Multiple Myeloma

Analyzing Long-Term Follow-Up Results From MonumenTAL-1 in Multiple Myeloma

ONCOLOGY Staff
August 17th 2025
Article

Experts discussed talquetamab's unique mechanism and favorable patient outcomes in relapsed/refractory multiple myeloma.

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD
August 15th 2025
Article

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Sanan Rasheed, MBBS;Umer Farooq, MBBS;Aiman Waheed, MBBS;Musharaf Khalid Bhutta, MBBS;Adnan Bhat, MD;Hamza Nazir, MBBS;Muhammad Hamza Gul, MBBS, MD;Ayesha Aman, MBBS;Zainab Ibrahim, MBBS;Abdul Baseer Wardak, MBBS
August 14th 2025
Article

Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.